|Bid||96.56 x 1800|
|Ask||99.11 x 800|
|Day's Range||97.73 - 98.83|
|52 Week Range||74.09 - 105.56|
|Beta (5Y Monthly)||0.47|
|PE Ratio (TTM)||30.02|
|Forward Dividend & Yield||3.50 (3.58%)|
|Ex-Dividend Date||Mar 09, 2023|
|1y Target Est||N/A|
Novo Nordisk (NVO) gets CHMP recommendation approval for Sogroya for expanded use in children and adolescents with growth hormone deficiency.
Bristol Myers (BMY) obtains Fast Track Designation from the FDA for milvexian, which is being developed in collaboration with Johnson and Johnson's Janssen.
The rising earnings estimate revisions are a strong sign that there could be more upside for Novartis and Novo Nordisk stock this year. Furthermore, both companies are leaders in critical areas of healthcare and remain sound long-term investments for 2023 and beyond.
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
Novo Nordisk (NVO) partners with Life Edit Therapeutics to discover and develop gene-editing therapies for rare and cardiometabolic diseases.
W.W. Grainger, Graphic Packaging, PulteGroup, Walmart and Novartis have been highlighted in this Screen of The Week article.
Novo Nordisk's (NVO) late-stage study of once-daily oral semaglutide 25 mg and 50 mg in obesity shows superior weight loss at week 68 compared with placebo.
Dividend stocks W.W. Grainger (GWW), Graphic Packaging (GPK), PulteGroup (PHM), Walmart (WMT) and Novartis (NVS) could be solid choices for your portfolio.
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
Most readers would already be aware that Novartis' (VTX:NOVN) stock increased significantly by 15% over the past three...
Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Bayer (BAYRY) tops on first-quarter 2023 earnings but misses on sales. Management reiterates guidance.
Novartis CEO pushes back against government attempts to direct pharma R&D
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Novartis CEO Vas Narasimhan joins Yahoo Finance Live to discuss company earnings, focusing efforts on fighting cancer, consumer health, and cutting roughly 10% of the global healthcare company’s experimental drug pipeline.
PulteGroup, Novartis, Boyd Gaming, Cummins and W.W. Grainger are part of the Zacks Screen of the Week article.
PulteGroup (PHM), Novartis (NVS), Boyd Gaming (BYD), Cummins (CMI) and W.W. Grainger (GWW) could be solid choices for your portfolio.